POTENTIAL UTILIZATION OF SOLID LIPID NANOPARTICLES AS A SOLUTION TO OPTIMIZE THE BIOAVAILABILITY OF ANTIDEPRESSANT DRUG SSRI IN IMPROVING THE EFFECTIVENESS OF DEPRESSION TREATMENT: A LITERATURE REVIEW
DOI:
https://doi.org/10.53366/jimki.v10i2.556Keywords:
solid lipid nanoparticles, major depressive disorder, antidepressant, bioavailabilityAbstract
Background: Currently, more than 264 million people globally suffer from major depressive disorder. Pharmacological treatments that are the main choice in cases of depression such as antidepressants are still constrained by low bioavailability, especially in the brain. Recent research shows the potential of solid lipid nanoparticles (SLN) as a specific antidepressant drug carrier agent and is able to increase bioavailability in the brain.
Methods: This literature review was compiled based on article searches in international databases, such as PubMed, Scopus, and Cochrane for the last 10 years until November 11, 2022. Study inclusion criteria included clinical and in vitro studies that measured differences in bioavailability of antidepressant drugs with and without SLN.
Discussion: In the research that has been conducted to date, it is known that SLN can carry duloxetine through the blood brain barrier effectively. This is evidenced by the behavioral despair test and BDNF concentrations that show a significant cure for depression and can match normal or control rats. In addition, in the biosafety test, SLN has also been shown to be safe for use in in vitro and in vivo experiments, namely through dermal administration mainly, and oral and parenteral, although it still requires further study.
Conclusion: In conclusion, SLN is a very potential solution to optimize the bioavailability of SSRI antidepressant drugs. Further clinical research is needed to confirm the efficacy and safety of using SLN as a carrier for antidepressant drugs in humans, especially in oral and parenteral administration due to the lack of data to date.
References
1. Depression [Internet]. [cited 2021 Mar 26]. Available from: https://www.who.int/news-room/fact-sheets/detail/depression
2. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;
3. Dubey S, Biswas P, Ghosh R, Chatterjee S, Dubey MJ, Chatterjee S, et al. Psychosocial impact of COVID-19. Diabetes Metab Syndr Clin Res Rev. 2020;
4. Salari N, Hosseinian-Far A, Jalali R, Vaisi-Raygani A, Rasoulpoor S, Mohammadi M, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: A systematic review and meta-analysis. Globalization and Health. 2020.
5. Johnson SU, Ebrahimi O V., Hoffart A. PTSD symptoms among health workers and public service providers during the COVID-19 outbreak. PLoS One. 2020;
6. Santoft F, Axelsson E, Öst LG, Hedman-Lagerlöf M, Fust J, Hedman-Lagerlöf E. Cognitive behaviour therapy for depression in primary care: Systematic review and meta-analysis. Psychological Medicine. 2019.
7. de Oliveira LDSSCB, Souza EC, Rodrigues RAS, Fett CA, Piva AB. The effects of physical activity on anxiety, depression, and quality of life in elderly people living in the community. Trends Psychiatry Psychother. 2019;
8. LaChance LR, Ramsey D. Antidepressant foods: An evidence-based nutrient profiling system for depression. World J Psychiatry. 2018;
9. Gautam S, Jain A, Gautam M, Vahia V, Grover S. Clinical Practice Guidelines for the management of Depression. Indian Journal of Psychiatry. 2017.
10. Katzung BG. Basic & Clinical Pharmacology, Fourteenth Edition. Basic and Clinical Pharmacology. 2018.
11. De Donatis D, Florio V, Porcelli S, Saria A, Mercolini L, Serretti A, et al. Duloxetine plasma level and antidepressant response. Prog Neuro-Psychopharmacology Biol Psychiatry. 2019;
12. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews. 2014.
13. Xue W, Wang P, Li B, Li Y, Xu X, Yang F, et al. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: An insight from molecular dynamics simulation study. Phys Chem Chem Phys. 2016;
14. O’Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: Clinical significance of in vitro and in vivo findings. British Journal of Pharmacology. 2012.
15. Rizvi SZH, Shah FA, Khan N, Muhammad I, Ali KH, Ansari MM, et al. Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model. Int J Pharm. 2019;
16. Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. Journal of Controlled Release. 2017.
17. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian Journal of Pharmaceutical Sciences. 2009.
18. Montasser I, Shahgaldian P, Perret F, Coleman AW. Solid lipid nanoparticle-based calix[n]arenes and calix-resorcinarenes as building blocks: Synthesis, formulation and characterization. Int J Mol Sci. 2013;14(11):21899–942.
19. Natarajan J, Baskaran M, Humtsoe LC, Vadivelan R, Justin A. Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. Artif Cells, Nanomedicine Biotechnol. 2017;
20. Kreuter J, Gelperina S. Use of nanoparticles for cerebral cancer. In: Tumori. 2008.
21. Annu, Rehman S, Md S, Baboota S, Ali J. Analyzing Nanotheraputics-Based Approaches for the Management of Psychotic Disorders. Journal of Pharmaceutical Sciences. 2019.
22. Yankelevitch-Yahav R, Franko M, Huly A, Doron R. The forced swim test as a model of depressive-like behavior. J Vis Exp. 2015;
23. Rana I, Khan N, Ansari MM, Shah FA, Din F ud, Sarwar S, et al. Solid lipid nanoparticles-mediated enhanced antidepressant activity of duloxetine in lipopolysaccharide-induced depressive model. Colloids Surfaces B Biointerfaces. 2020;
24. Jeon SW, Kim YK. Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness? World J Psychiatry. 2016;
25. Mostafa DAE, Khalifa MKA, Gad SS. Zolmitriptan brain targeting via intranasal route using solid lipid nanoparticles for migraine therapy: Formulation, characterization, in-vitro and in-vivo assessment. Int J Appl Pharm. 2020;
26. Doktorovová S, Kovačević AB, Garcia ML, Souto EB. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2016;
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Nathaniel Gilbert Dyson
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.